Anika Therapeutics (ANIK) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue rose 10% year over year to $30.59 million, beating consensus estimates of roughly $29.4 million.
• GAAP (Generally Accepted Accounting Principles) loss from continuing operations narrowed sharply to $0.02 per share, versus a $0.22 loss a year earlier.
• Adjusted EPS (earnings per share) reached $0.29, up from $0.04 in the prior-year period, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed to $5.1 million.
• Commercial channel revenue hit a record $14.0 million, up 17%, led by 19% growth in international OA (osteoarthritis) pain management and more than 30% growth in Integrity.
• Management raised the lower end of its full-year 2026 revenue growth guidance to 6%–10% but flagged an FDA (U.S. Food and Drug Administration) "not approvable" decision for its Hyalofast device.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Interested in data-driven market insights? Discover Trending AI Robots.

Earnings Context and Why It Matters

Anika Therapeutics is a global joint-preservation and hyaluronic acid innovation company operating across two main channels: Commercial and OEM (original equipment manufacturer). Its Q3 2026 report, covering the three months ended September 30, 2026, matters because it tests whether the company can sustain top-line momentum while navigating a mixed profitability picture. After several quarters of clean beats, this report read as more balanced: revenue exceeded expectations, but GAAP results and stock-based compensation costs drew scrutiny. Investors are also watching closely because Anika is balancing near-term commercial execution against longer-term pipeline milestones, including its Cingal NDA (New Drug Application) and a regulatory setback for Hyalofast.

Reported Results

Anika reported third quarter 2026 revenue of $30.59 million, a 10% increase from $27.82 million a year earlier and modestly above the consensus estimate near $29.4 million. Commercial channel revenue rose 17% to a record $14.0 million, while OEM channel revenue increased 5% to $16.6 million.

On a GAAP basis, the loss from continuing operations narrowed to $0.3 million, or $0.02 per share, compared with a loss of $3.2 million, or $0.22 per share, in the prior-year quarter. Net loss was $0.31 million versus $2.33 million a year ago. Adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share, up from $0.04 a year earlier. Adjusted EBITDA rose to $5.1 million from $0.9 million, though it declined sequentially from $7.1 million in Q2, largely on OEM shipment timing. Gross margin expanded to 62% from 56% year over year but slipped from 65% in the second quarter, reflecting product mix tied to the reintroduced Hyalomatrix wound product.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Anika Therapeutics, it offers a structured way to surface relevant opportunities across the medical technology landscape.

Market Reaction and Investor Sentiment

Heading into the report, sentiment reflected Anika's strong year-to-date run, with shares having gained more than 100% since the start of 2026. The quarter delivered a top-line beat, but the market also weighed the GAAP loss, elevated stock-based compensation, and the Hyalofast regulatory setback. The mix of a raised 2026 guidance floor, a new 10-year Hyvisc distribution agreement with Boehringer Ingelheim, and a cut to Commercial channel growth expectations left investors parsing both the near-term momentum and the pipeline's longer-term trajectory. The result was a more balanced, and in some respects mixed, interpretation than the company's prior beat-and-raise quarters.

Forward Outlook and Key Factors to Monitor

Management raised the lower end of its full-year 2026 total-company revenue growth guidance to 6%–10%, up from 5%–10%, while adjusting channel-level expectations. OEM revenue growth is now guided to 5%–9%, up from 0%–5%, while Commercial channel growth was lowered to 9%–13% from 12%–18%. The adjusted EBITDA margin outlook was also raised to 15%–17%, from 13%–17%.

For 2027, Anika reaffirmed total-company revenue growth of flat to 5%, with Commercial channel growth of 5%–10% and OEM revenue expected to be flat to modestly lower. The company's forward guidance does not include any U.S. Hyalofast revenue.

Investors should monitor several key items. First, the FDA's "not approvable" decision on the Hyalofast PMA (Premarket Approval) application in October is a notable setback, and management's next steps will be closely watched. Second, the Cingal NDA is expected to be submitted before year-end 2027, with bioequivalence and chemistry, manufacturing, and controls work still in progress. Third, the new Hyvisc agreement includes roughly $8 million in expected payments, with a $4 million upfront payment anticipated in the first quarter of 2027. Finally, gross margin trends and OEM shipment timing will remain important, given the sequential margin step-down and the inventory build supporting higher output.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations